BACKGROUND: The aim of this study was to assess if FDG-PET could guide dose prescription heterogeneity and decrease arbitrary location of hotspots in SBRT. METHODS: For three @entity1 with @entity5 , a CT-simulation and a FDG-PET were registered to define respectively the PTVCT and the biological target volume (BTV). Two plans involving volumetric modulated arc therapy (VMAT) and @entity15929 ( @entity15929 ) were calculated. The first plan delivered 4 * 12 Gy within the @entity343 (CT) and the second plan, with @entity15929 , 4 * 12 Gy and 13.8 Gy (115% of the prescribed dose) within the @entity343 (CT) and the BTV respectively. The Dmax- @entity343 (CT) had to be inferior to 60 Gy (125% of the prescribed dose). Plans were evaluated through the D95%, D99% and Dmax- @entity343 (CT), the D2 cm, the R50% and R100% and the dice similarity coefficient (DSC) between the isodose 115% and BTV. DSC allows verifying the location of the 115% isodose (ideal value   =   1). RESULTS: The mean @entity343 (CT) and BTV were 36.7 (  12.5) and 6.5 (  2.2) cm3 respectively. Both plans led to similar target coverage, same doses to the OARs and equivalent fall-off of the dose outside the @entity343 (CT). On the other hand, the location of hotspots, evaluated through the DSC, was improved for the @entity15929 plans with a mean DSC of 0.31 and 0.45 for the first and the second plans respectively. CONCLUSIONS: Use of PET to decrease arbitrary location of hotspots is feasible with VMAT and @entity15929 for @entity2 .

Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for XXXX with volumetric modulated arc therapy: a feasibility study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage I lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity343 :: ('187978', 'Species') :: ['PTV'] @entity15929 :: ('MESH:C565771', 'Disease') :: ['SIB', 'simultaneous integrated boost']
@entity2 :: (MESH:D008175,Disease) :: ['lung cancers']
